SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering for the next generation of cell and gene therapies, has appointed Chad May, Ph.D., as the company's Chief Scientific Officer. In this new role, Dr. May will lead the research and development of Serotiny’s novel therapeutics programs.
"Chad is a fantastic addition to the Serotiny leadership team," said Serotiny Chief Executive Officer Colin Farlow. "His deep expertise and successful track record in novel therapeutic design and development, his strategic vision, and his proven ability to advance therapies against solid tumors to the clinic, will provide strong leadership as we progress our platform and pipeline programs."
Dr. May brings to Serotiny extensive knowledge and proficiency gained through more than 20 years leading oncology research and development programs across a broad array of tumor types and therapeutic modalities. Most recently, as senior vice president of Research and Development at Maverick Therapeutics (acquired by Takeda in April 2021), he progressed two solid tumor targeting conditionally active T cell engagers, TAK-186 and TAK-280, through preclinical IND enabling studies to first-in-human clinical trials. Prior to that, Dr. May served as senior director of Targeted Immunotherapy for Pfizer, developing research strategy and overseeing execution of multiple immuno-oncology programs including T cell engagers, antibody drug conjugates, and monoclonal antibodies.
He also spent nine years at ImClone Systems (acquired by Eli Lilly in 2008) leading several early-stage monoclonal antibody and radioimmunotherapy programs.
Dr. May holds a B.S. in Genetics and Cell Biology from the University of Minnesota and a Ph.D. in Immunology from the Weill Cornell Graduate School of Medical Sciences, in a joint program with the Sloan Kettering Institute.
Dr. May commented, "It is very exciting for me to be joining the innovative team at Serotiny. Having advanced several next generation therapies from concept to the clinic, I am greatly impressed by the elegance and power of Serotiny’s discovery platform to generate novel and effective therapies for the many patients with unmet medical needs.”
About Serotiny
Serotiny is a pre-clinical discovery company building better gene and cell therapies through high-throughput engineering of therapeutic Multi-Domain Proteins (tMDPs) such as Chimeric Antigen Receptors (CARs) and next generation gene editors. At the heart of Serotiny’s technology is a discovery platform that harmonizes computationally aided protein design, high-throughput cellular assays, and next generation sequencing. Serotiny’s platform enables a cross disciplinary approach to engineering large and often unstructured multi-domain proteins, applying expertise from synthetic biology, immunology, machine learning, software engineering, and bioinformatics. For more info visit www.serotiny.bio, or contact Colin Farlow at info@serotiny.bio.
